XML 32 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-Based Payments (Details Textual) (USD $)
3 Months Ended 6 Months Ended
Oct. 31, 2013
Oct. 31, 2012
Oct. 31, 2013
Oct. 31, 2012
Share-based Compensation, Total $ 476,000 $ 624,000 $ 1,028,000 $ 1,364,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 1.06 $ 0.26 $ 0.94 $ 0.52
Share-based Compensation Arrangement by Share-based Payment Award, Vesting Period, Fair Value     $ 7,500 $ 11,000
Class of Warrant or Right, Outstanding 3,276,667   3,276,667  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross     1,645,000  
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price     $ 1.18  
Service Based Vesting Provisions [Member]
       
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total     5,000,000  
Service and Performance Based Vesting Provisions [Member]
       
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total     5,000,000  
Employees [Member]
       
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross     6,400,000  
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price     $ 1.23  
Chief Executive Officer and President [Member]
       
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross     10,000,000  
April 2011 Private Placement [Member]
       
Warrants Issued During Period for Common Stock     1,266,667  
Share-based Compensation Arrangement by Share-based Payment Award, Description     The performance-based conditions, which had to be met prior to vesting to occur included: (i) closing of one or more financings of the Company in the aggregate amount of at least $5,000,000; (ii) bringing in new Company management; (iii) launching of personalized medicine (oncology) business; and (iv) commencing implementation of the Company’s business plan. The service-based options, like all of the Company’s service-based options, are expensed on a straight-line basis. Since the straight-line method is not available for performance or market-based share-based payments, the 5,000,000 performance-based options are being expensed on an accelerated basis.  
January 2013 Private Placement [Member]
       
Warrants Issued During Period for Common Stock     1,860,000  
Equity Instrument [Member]
       
Class of Warrant or Right, Outstanding 150,000   150,000